Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care-Reference-Cited by-同舟云学术

Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care

Published:2018-01-09 Issue:5 Volume:47 Page:418-421
ISSN:0300-9742
Container-title:Scandinavian Journal of Rheumatology
language:en
Short-container-title:Scandinavian Journal of Rheumatology

Author:

Glintborg B¹²,Kringelbach T³,Bolstad N⁴,Warren DJ⁴,Eng G⁵,Sørensen IJ¹⁶,Loft AG⁷,Hendricks O⁸,Hansen IMJ⁹,Linauskas A¹⁰,Nordin H⁵,Kristensen S¹¹,Lindegaard H¹²,Jensen DV²,Goll GL¹³,Høgdall E¹⁴,Gehin J¹⁵,Enevold C¹⁶,Nielsen CH¹⁶,Krogh NS¹⁷,Johansen JS⁶¹⁴¹⁸,Hetland ML¹⁶

Affiliation:

1. The Danish Rheumatologic Biobank, the DANBIO Registry and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark

2. Department of Rheumatology, Gentofte and Herlev Hospital, Copenhagen University Hospital, Gentofte, Denmark

3. The Danish Rheumatologic Biobank, Department of Pathology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark

4. Department of Medical Biochemistry, Oslo University Hospital, Radiumhospitalet, Oslo, Norway

5. Department of Rheumatology, Zealand University Hospital, Køge, Denmark

6. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

7. Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark

8. King Christian X’s Hospital for Rheumatic Diseases, Graasten, Denmark

9. Department of Rheumatology, Odense University Hospital, Svendborg Hospital, Svendborg, Denmark

10. Department of Rheumatology, North Denmark Regional Hospital, Hjørring, Denmark

11. Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark

12. Department of Rheumatology, Odense University Hospital, Odense, Denmark

13. Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

14. The Danish Rheumatologic Biobank, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark

15. Department of Medical Biochemistry, Oslo University Hospital, Radiumhospitalet, Norway

16. Center for Rheumatology and Spine Diseases, Institute for Inflammation Research (IIR), Rigshospitalet, Copenhagen University Hospital, Glostrup, Denmark

17. Zitelab, Copenhagen, Denmark

18. Department of Medicine and Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark

Funder

AbbVie

Publisher

Informa UK Limited

Subject

Immunology,General Medicine,Immunology and Allergy,Rheumatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/03009742.2017.1376110

Reference7 articles.

2. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry

3. RADS. Guidelines for the use of the biosimilars infliximab and etanercept (http://www.regioner.dk/media/3488/rads-notat-om-anvendelsen-af-biosimilaere-juni-2016.pdf). Accessed 4 October 2017.

4. Bio- and Genome Bank Denmark (http://www.regioner.dk/rbgben). Accessed 4 October 2017.

5. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable;Advances in Therapy;2021-03-21

2. Effects of successive switches to different biosimilars infliximab on immunogenicity in chronic inflammatory diseases in daily clinical practice;Seminars in Arthritis and Rheumatism;2020-12

3. Real-world observational study of biosimilars in inflammatory arthritis treatment: a systematic literature review;Expert Opinion on Biological Therapy;2020-10-16

4. The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars;European Journal of Clinical Pharmacology;2019-11-01

5. Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial;Journal of Internal Medicine;2019-04-12